Annotation Detail
Information
- Associated Genes
- VHL
- Associated Variants
-
VHL LOSS-OF-FUNCTION
VHL LOSS-OF-FUNCTION - Associated Disease
- renal cell carcinoma
- Source Database
- CIViC Evidence
- Description
- A randomized, open-label phase 2 study, encompassing 85 patients, to compare the efficacy of dual PIK3/mTOR Inhibitor Apitolisib and mTORC1 inhibitor Everolimus in patients who progressed on or after antiangiogenetic therapy (VEGFR). There was a trend towards association between deleterious VHL alterations and progression-free-survival in the Everolimus arm only.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5323
- Gene URL
- https://civic.genome.wustl.edu/links/genes/58
- Variant URL
- https://civic.genome.wustl.edu/links/variants/160
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Renal Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Everolimus
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26951309
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Everolimus | Sensitivity | true |